| Literature DB >> 36004914 |
Nicolas Touya1, Ayako Washio2, Chiaki Kitamura2, Adrien Naveau1,3,4, Yasuhiko Tabata5, Raphaël Devillard1,3,4, Olivia Kérourédan1,3,4,5.
Abstract
As the need for efficient, sustainable, customizable, handy and affordable substitute materials for bone repair is critical, this systematic review aimed to assess the use and outcomes of silica-derived inks to promote in vivo bone regeneration. An algorithmic selection of articles was performed following the PRISMA guidelines and PICO method. After the initial selection, 51 articles were included. Silicon in ink formulations was mostly found to be in either the native material, but associated with a secondary role, or to be a crucial additive element used to dope an existing material. The inks and materials presented here were essentially extrusion-based 3D-printed (80%), and, overall, the most investigated animal model was the rabbit (65%) with a femoral defect (51%). Quality (ARRIVE 2.0) and risk of bias (SYRCLE) assessments outlined that although a large majority of ARRIVE items were "reported", most risks of bias were left "unclear" due to a lack of precise information. Almost all studies, despite a broad range of strategies and formulations, reported their silica-derived material to improve bone regeneration. The rising number of publications over the past few years highlights Si as a leverage element for bone tissue engineering to closely consider in the future.Entities:
Keywords: 3D printing; biofabrication; bioprinting; bone regeneration; in vivo; ink; silica; silicium; silicon; tissue engineering
Year: 2022 PMID: 36004914 PMCID: PMC9404869 DOI: 10.3390/bioengineering9080388
Source DB: PubMed Journal: Bioengineering (Basel) ISSN: 2306-5354
Systematic search strategy (PICO model).
| Category | |
|---|---|
| Population | Animals with created bone defect |
| Intervention | Printed silica-based ink |
| Comparison | Untreated or controls |
| Outcome | Results of bone regeneration |
| Search combination | PubMed: ((silic*[Title/Abstract]) AND (print*[Title/Abstract]) AND (bone[Title/Abstract])) NOT (silicone[Title/Abstract]) AND ((in vivo[Title/Abstract]) |
| Language | English |
| Electronic databases | MEDLINE/PubMed, Scopus, Web Of Science |
Figure 1Flow diagram of study identification following PRISMA guidelines.
Figure 2Science mapping analysis of scientific domains: keyword co-occurrence networks among the included articles. Each node size is proportionate to its degree and link’s thickness represents the tie strength.
Figure 3Overall animal/bone defect models and printing strategies repartition among the reviewed articles. Rabbit, femur and extrusion constituted the majority of the articles’ focuses.
Bone repair outcomes of the scoped articles sorted by silicon form, role and investigated formulation.
| Si Form | Si Role | % of Articles | Main Focus | Number of Articles | Outcome | Publications |
|---|---|---|---|---|---|---|
| Si is in native material | with a primary role | 21.6% | CaSiO3 scaffolds | 2 |
improved bone regeneration (vs. CaSiO3/Fe composite or pure Fe scaffold) improved bone regeneration (vs. B-TCP) | Ma 2018 [ |
| MgCaSi compounds | 3 |
MCS/GA/PCL: 30% MCS formulation improved bone regeneration (vs. 0 and 15%) CaSi–Mg6/PVA: Double layer CSi/PVA improved bone regeneration at 12 weeks (vs earlier times and vs. CaSi-Mg6/PVA single composites) Mg2% CaSi/PVA6%: improved bone regeneration (vs. Ti scaffold) | Zhang 2018 [ | |||
| Sr5(PO4)2SiO4 (SPS) bio-ceramics | 1 | improved ICRS score (vs. CTR and TCP). Improved neobone structural organization | Deng 2018 [ | |||
| borosilicate glass (BG) with MBG | 1 | improved bone regeneration (vs. BG alone) | Qi 2018 [ | |||
| MBG/CSH/PCL | 1 | 60% MBG: improved bone regeneration (vs. lower % BG or CSH/PCL alone) | Qi 2017 [ | |||
| C3S materials | 2 |
C3S/MBG: improved bone regeneration (vs. C3S alone and vs. ctrl) C3S/Col1: no significant bone regeneration (vs. ctrl), or by adding cells (SCAPs) | Pei 2016 [ | |||
| LiCaSi | 1 | L2C4S: improved bone regeneration (vs. β-TCP) | Chen 2019 [ | |||
| with a secondary role (1/2) | 56.8% | Organic doping | 9 |
dECM coating CS/PCL scaffold: improved bone regeneration (vs. CS/PCL alone) Ginsenoside Rb1-loaded CS scaffold: improved bone regeneration (vs. CS alone) Caffeic acid coated MTA/PCL: improved bone regeneration (vs. no coating) FGF-loaded CS/PCL scaffold: improved bone regeneration (vs. CS/PCL alone) SVVYGLR grafted on CS scaffold: improved bone regeneration (vs. CS alone) BMSCs-loaded Mg8-CS scaffold: no significant difference in bone formation (vs. no BMSCs loading) rhBMP-2-loaded MS/CPC scaffold: improved bone regeneration (vs. CS alone) FGF-2-loaded gelatin/MgCS/PCL: improved bone regeneration (vs. gelatin/MgCS/PCL vs. MgCS/PCL) Zein/n-MS/PCL: improved bone regeneration (20%ZN/30%n-MS/50%PCL vs. 10%ZN/30%n-MS/60%PCL vs. 0%ZN/30%n-MS/70%PCL) | Wu 2019 [ | |
| Si is in native material | with a secondary role (2/2) | Non-organic doping | 8 |
Cu-loaded silica nanoparticles in PLGA: improved bone regeneration (vs. SN alone or PLGA alone) SrCS/PCL scaffold: improved bone regeneration (vs. CS/PCL alone) Mg/Sr-doped CS: improved bone regeneration (vs. MgCS or SrCS) Graphene/CS scaffold: improved bone regeneration (vs. 0 graphene) Csi-Mg10/PVA6%/alginate/chitosan: improved bone regeneration (vs. Csi alone) Csi-Mg14/PVA 6%: improved bone regeneration (vs. every inferior Csi-Mg compound) CsiMg4@CsiMg10-p/PVA 6%: improved bone regeneration (vs. CsiMg4@CsiMg10 vs. CsiMg10@CsiMg4 vs. CsiMg10@CsiMg4-p) (10%Mg90%Ca)Si: 8 weeks lower but 16 weeks improved bone regeneration (vs. bredigite and vs. pure CaSi) | Lian 2020 [ | |
| Multiple doping | 2 |
BMP2-loaded MBG-coated 1393BG: improved bone regeneration (vs. 1393 alone) (BMP2-loaded > MBG + 1393) hGF and Sr-loaded CS: improved bone regeneration (vs. Sr loading alone and vs. CS alone) | Wang 2020 [ | |||
| New scaffold as whole | 7 |
LCS (Li2Ca2Si2O7): improved bone regeneration and ICRS (vs. ctrl and β-TCP) B-BG and 30 wt% sodium alginate: improved bone regeneration (vs. HA and ctrl) Al-β-Ca2SiO4: improved bone regeneration (15%Al vs. C2S alone) Si-HA/DMB/PCL: qualitatively appreciated bone colonization MPC3-BG: improved bone regeneration (vs. MPC alone and ctrl) AW/PLA: improved bone regeneration (vs. AW alone or PLA alone) akermanite (Ca(2)MgSi(2)O(7))/PVA: improved bone regeneration (vs. β-TCP) | Deng 2018 [ | |||
| porosity | 2 |
600 µm pores: most bone ingrowth, good mechanical strength and excellent Mg2+ ion release potential (vs. 480 and 720 µm pores) 200–320 µm pores: slower degradability but improved bone regeneration (at 16 weeks vs. 450–600 µm pores) | Qin 2022 [ | |||
| surface treatment | 1 | C3S with nanoneedle surface structure: improved bone regeneration (vs. no treatment) | Yang 2017 [ | |||
| Si is an additive material | with a primary role | 19.6% | Doping | 9 |
SiO2 and ZnO in β-TCP scaffolds: improved bone regeneration (vs. no doping) Si-BG-loaded PLA scaffolds: equal integration and bone regeneration (vs. Ti6Al4V and vs. empty defects) SiO2 and MgO (0.5%) in β-TCP scaffolds: improved bone regeneration (vs. no doping) MgO, ZnO, SrO and/or SiO2 in TCP: Mg/Si-doped scaffold improved bone regeneration (vs. all others and pure TCP) Si + 4 and Fe + 3 doping in TCP: enhanced blood vessels and osteoid tissue formation (vs. TCP alone) 100 nm Si particles in PCL: enhanced bone regeneration (vs. 500 and 800 nm particles) SiP nanosheets in GelMA-PEGDA: enhanced angiogenic activity and osteogenic induction for bone regeneration (vs. BP/GelMA-PEGDA and GelMA-PEGDA alone) SiO2 (0.5%) and ZnO (0.25%) in β-TCP scaffolds: improved bone regeneration (vs. no doping) 10% Zn-Silicate/HA/Col: improved bone regeneration (vs. 10% Zn-Silicate/HA/Col + P38 inhibitor and 10% Zn-Silicate/HA…+ Col ERK1/2 inhibitor) | Nandi 2018 [ |
| Coating | 1 |
MBG-BG-coated Ti-6Al-4V: improved bone regeneration (vs. no coating) | Zhang 2021 [ | |||
| with a secondary role | 2% | Chitosan + BGn70 + Tri | 1 | Chit@BGn70 + Tri (tri-molecule dexamethasone-FGF2-phenamil-loaded chitosan/bioglass-coated PCL scaffold): improved bone regeneration (vs Chit@BGn70 vs. ctrl) | Kim 2021 [ |
Figure 4Overall silicon form and role repartition among the scoped articles.
Decision table of articles sorting.
| Category | Si Is in the Native Material | Si Is Primary in the Study |
|---|---|---|
| 1a | Yes | Yes |
| 1b | Yes | No |
| 1c | No | Yes |
| 1d | No | No |
Figure 5Visualizing risk of bias assessments of studied articles following (A,B) SYRCLE and (C) ARRIVE 2.0 guidelines with robvis tool.